BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
They relied on marijuana to get through the day. But then days felt impossible without it - 2Sixteen Kenyans missing in Russia after army recruitment
- 3Health insurance premiums rose nearly 3x the rate of worker earnings over the past 25 years
- 4Vote in favor of the juice that you love for its medical advantages!
- 5Find Your Internal Culinary expert: Cooking Strategies and Recipes
- Germany ready to assist Syria's reconstruction, says foreign minister
- Figure out How to Recognize Early Indications of Depressions
- Vote In favor of Your Favored Keeping an eye on
- A Manual for Extravagant Vehicles Available in 2024
- Spanish woman, 25, dies by legal euthanasia in case that drew national spotlight
- Architect Frank Gehry has died: See his most iconic buildings
- Finding the Universe of Craftsmanship: Individual Encounters in Imagination
- Affordable Care Act enrollment is slightly ahead of last year, despite expiring subsidies
- Two Passover initiatives target isolation and safety for Israel’s elderly
